Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial

被引:28
|
作者
Thorleifsdottir, Ragna Hlin [1 ,2 ]
Sigurdardottir, Sigrun Laufey [3 ]
Sigurgeirsson, Bardur [1 ]
Olafsson, Jon Hjaltalin [1 ]
Sigurdsson, Martin Ingi [4 ]
Petersen, Hannes [5 ]
Gudjonsson, Johann Eli [6 ]
Johnston, Andrew [6 ]
Valdimarsson, Helgi [3 ]
机构
[1] Univ Iceland, Dermatol Sect, Fac Med, Reykjavik, Iceland
[2] Uppsala Univ, Dept Med Sci, Dermatol, Uppsala, Sweden
[3] Landspitali Natl Univ Hosp Iceland, Dept Immunol, Reykjavik, Iceland
[4] Landspitali Natl Univ Hosp Iceland, Dept Anesthesiol & Crit Care, Reykjavik, Iceland
[5] Landspitali Natl Univ Hosp Iceland, Dept Otolaryngol Head & Neck Surg, Reykjavik, Iceland
[6] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI USA
关键词
chronic plaque psoriasis; streptococcal throat infection; tonsillectomy; health-related quality of life; Psoriasis Disability Index; Psoriasis Life Stress Inventory; QUALITY-OF-LIFE; STREPTOCOCCAL THROAT INFECTIONS; RECALCITRANT PSORIASIS; GUTTATE PSORIASIS; PERIPHERAL-BLOOD; VULGARIS; CELLS; PATHOGENESIS; IMPROVEMENT; ONSET;
D O I
10.2340/00015555-2562
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a chronic inflammatory skin disease with profound effects on patients' health-related quality of life (HRQoL). Twenty-nine patients with plaque psoriasis and a history of streptococcal-associated psoriasis exacerbations were randomly assigned to tonsillectomy (n = 15) or control (n = 14) groups and followed for 24 months. Patients were evaluated with the Psoriasis Disability Index, Psoriasis Life Stress Inventory and Psoriasis Area and Severity Index. HRQoL and psoriasis-related stress improved significantly in the tonsillectomy group compared with the control group (p = 0.037 and p = 0.002, respectively), with a mean 50% improvement in HRQoL and a mean 59% improvement in psoriasis-induced stress. Clinical improvement correlated significantly with improved HRQoL (r = 0.297, p = 0.008) and psoriasis-related stress (r = 0.310, p = 0.005). Of the tonsillectomized patients, 87% concluded that the procedure was worthwhile. Tonsillectomy may improve quality of life for selected patients with plaque psoriasis.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 50 条
  • [41] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Cabaleiro, Teresa
    Solano-Lopez, Guillermo
    Marquez, Beatriz
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
  • [42] IDENTIFYING PREDICTORS OF HIGH RESPONSE LEVELS IN IXEKIZUMAB-TREATED PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Reich, Kristian
    Eyerich, Kilian
    Costanzo, Antonio
    Lebwohl, Mark
    Garrelts, Alyssa
    Saure, Daniel
    Schuster, Christopher
    Blauvelt, Andrew
    Porsdal, Vibeke
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 46 - 46
  • [43] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
  • [44] Identifying predictors of high response levels in ixekizumab-treated patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Eyerich, K.
    Costanzo, A.
    Lebwohl, M.
    Garrelts, A.
    Saure, D.
    Schuster, C.
    Blauvelt, A.
    Machacek, C.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (02) : E22 - E23
  • [45] Identifying predictors of high response levels in ixekizumab-treated patients with moderate-to-severe plaque psoriasis
    Reich, Kristian
    Eyerich, Kilian
    Costanzo, Antonio
    Lebwohl, Mark
    Garrelts, Alyssa
    Saure, Daniel
    Schuster, Christopher
    Blauvelt, Andrew
    Truong, David
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 78 - 78
  • [46] Apremilast in moderate-to-severe plaque psoriasis (ESTEEM 2 trial)
    Anstey, Alex
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : E23 - E23
  • [47] Clinically meaningful improvements in patient-reported outcomes for patients with moderate to severe psoriasis receiving etanercept
    Krueger, G
    Woolley, J
    Zitnik, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A55 - A55
  • [48] Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis
    Khatri, S.
    Amir, Y.
    Min, M.
    Goldblum, O.
    Solotkin, K.
    Yang, F.
    Ridenour, T.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 74
  • [49] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
    Silverberg, Jonathan I.
    Cohen, Arnon D.
    Stander, Sonja
    Feeney, Claire
    Valdez, Hernan
    Biswas, Pinaki
    Cameron, Michael C.
    DiBonaventura, Marco
    Gerber, Robert A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [50] Rapid Onset of Response and Patient-reported Outcomes After OnabotulinumtoxinA Treatment of Moderate-to-Severe Glabellar Lines
    Beer, Kenneth R.
    Boyd, Charles
    Patel, Rina K.
    Bowen, Beta
    James, Steven P.
    Brin, Mitchell F.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (01) : 39 - 44